Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Astrazeneca to gain rights to Almirall's respiratory franchise

Wed, 30th Jul 2014 08:16

Astrazeneca has struck a deal with drug developer Almirall for the rights to the Spanish group's respiratory franchise. Under the agreement, which includes an initial consideration of $875m, the FTSE 100-listed company will gain the rights for the development and commercialisation of Almirall's existing proprietary respiratory business, including rights to revenues from Almirall's existing partnerships, as well as its pipeline of investigational novel therapies.Astra will make further payments of up to $1.22bn based on development, launch, and sales-related milestones. The Anglo-Swedish drugs giant has also agreed to make various sales-related payments. The franchise includes Eklira, which according to Almirall's first half results has grown 50% to €58.0m, equal to 14.4% of the company's total sales. The product has achieved increased market share in all of its key geographies. The respiratory franchise generated sales of €123.5m, up 13.6% compared to the first half of 2013. "The business combination will give Astrazeneca immediate access to on-market revenues, contributing to the company's return to growth," it said. It expects the transaction to be neutral to core earnings per share in 2015 and accretive from 2016, with no impact on 2014. The group said it planned to finance the transaction from existing cash resources and short-term credit facilities.Under the agreement, Almirall Sofotec, an Almirall subsidiary focused on the development of innovative proprietary devices, will also transfer to Astrazeneca.The group's Chief Executive Officer, Pascal Soriot, said: "Our agreement with Almirall brings strategic and long-term value to AstraZeneca's strong respiratory franchise, one of our key growth platforms. We will benefit from immediate and growing product revenues which we anticipate will be rapidly accretive to earnings. "Chronic respiratory disease affects hundreds of millions of people around the world. By combining our innovative portfolios and leveraging AstraZeneca's global scientific and commercial capabilities, we will strengthen our ability to address the entire spectrum of care in asthma and COPD." Shares in Astrazeneca were up 1.1% to 4,370.5p at 08:16 on Wednesday.NR
More News
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more
26 Dec 2023 21:26

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 21:00

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 19:41

Wall Street gains on final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
22 Dec 2023 08:47

AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone"

(Alliance News) - AstraZeneca PLC and Ionis Pharmaceuticals Inc on Friday celebrated the news that their drug eplontersen was approved by the US Food & Drug Administration.

Read more
22 Dec 2023 07:50

LONDON BRIEFING: UK on brink of recession as economy contracts in Q3

(Alliance News) - Stocks in London are likely to open lower on Friday, with investors feeling frosty ahead of a US inflation print this afternoon, amid sobering UK economic growth data.

Read more
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.